Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ZYMEthis companyZymeworks Inc.	$30.36	-24.38×	7.39×	18.72×	-28.56×	-158.3%	100.0%	-87.3%	-76.6%	-30.2%	-30.1%	-1.7%	0.07×	0.33×	0×	5.52×	0.0%	2	-0.57	1	D+
ALXOALX Oncology Holdings Inc.	$1.22	-0.59×	2.33×	0×	-0.5×	-90.6%	0.0%	0.0%	0.0%	-391.4%	-262.0%	-139.1%	0.2×	0.11×	-64.93×	2.07×	0.0%	2	-2.66	2	C
CBIOCrescent Biopharma, Inc.	$14.16	-0.8×	0.61×	11.39×	0.59×	61.0%	100.0%	-1407.5%	-1419.6%	-75.8%	-74.6%	-117.0%	0.01×	1.41×	-69.85×	6.56×	0.0%	3	11.24	2	C+
CLDXCelldex Therapeutics, Inc.	$31.21	-6.96×	3.43×	1,204.09×	-6.97×	-99.2%	100.0%	-19160.0%	-17253.3%	-49.1%	-53.9%	-11.8%	0×	0.1×	0×	10.49×	0.0%	2	16.42	2	C
CTMXCytomX Therapeutics, Inc.	$2.08	-28.4×	5.93×	7.71×	-36.76×	-283.4%	100.0%	-29.3%	-22.8%	-17.5%	-20.5%	-12.9%	0.04×	0.53×	0×	3.09×	0.0%	1	1.34	2	C
IMNMImmunome, Inc.	$19.48	-8.84×	2.96×	270.32×	-5.86×	-62.3%	57.4%	-3084.8%	-3060.0%	-33.5%	-33.5%	-10.7%	0.01×	3.1×	0×	14.69×	0.0%	2	31.88	2	C+
Peer median	—	-6.96×	2.96×	11.39×	-5.86×	-90.6%	100.0%	-1407.5%	-1419.6%	-49.1%	-53.9%	-12.9%	0.01×	0.53×	0×	6.56×	0.0%	2	11.24	2	—